Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Halozyme Buys Antares, Expanding Drug Delivery Ambitions

Executive Summary

Halozyme will pay $960m to acquire Antares, gaining an auto-injector drug delivery platform, which the company said has broad licensing potential, as well as a commercial portfolio.

You may also be interested in...

Teva’s Partner Antares Swallowed Up By Halozyme In $960m Deal

For just shy of $1bn, Halozyme Therapeutics is set to acquire drug development and injectable technology specialist Antares Pharma, providing it with a portfolio and pipeline of Teva products through a long-term partnership.

Antares sinks on FDA safety data request

Shares of Antares Pharma dropped more than 11% in morning trading on 13 January after the company revealed the FDA wants the firm to create a larger safety database for its experimental drug QuickShot Testosterone after a single reported case of hives in a Phase II study participant.

Antares Pharma names new CFO

New Jersey-based Antares Pharma, which develops self-administered parenteral pharmaceutical products, has named James E Fickenscher senior vice-president and chief financial officer. Mr Fickenscher has more than 25 years of experience in the pharmaceutical industry. Most recently, he was chief financial officer of Auxilium Pharmaceuticals from May 2005 until August 2014.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts